Blood metabolites predicting mild cognitive impairment in the study of Latinos-investigation of neurocognitive aging (HCHS/SOL)

Shan He; Einat Granot-Hershkovitz; Ying Zhang; Jan Bressler; Wassim Tarraf; Bing Yu; Tianyi Huang; Donglin Zeng; Sylvia Wassertheil-Smoller; Melissa Lamar; Martha Daviglus; Maria J. Marquine; Jianwen Cai; Thomas Mosley; Robert Kaplan; Eric Boerwinkle; Myriam Fornage; Charles DeCarli; Bruce Kristal; Hector M. Gonzalez; Tamar Sofer

doi:10.1002/dad2.12259

Blood metabolites predicting mild cognitive impairment in the study of Latinos-investigation of neurocognitive aging (HCHS/SOL)

Shan He, Einat Granot-Hershkovitz, Ying Zhang, Jan Bressler, Wassim Tarraf, Bing Yu, Tianyi Huang, Donglin Zeng, Sylvia Wassertheil-Smoller, Melissa Lamar, Martha Daviglus, Maria J. Marquine, Jianwen Cai, Thomas Mosley, Robert Kaplan, Eric Boerwinkle, Myriam Fornage, Charles DeCarli, Bruce Kristal, Hector M. GonzalezTamar Sofer

Epidemiology & Population Health

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Introduction: Blood metabolomics-based biomarkers may be useful to predict measures of neurocognitive aging. Methods: We tested the association between 707 blood metabolites measured in 1451 participants from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL), with mild cognitive impairment (MCI) and global cognitive change assessed 7 years later. We further used Lasso penalized regression to construct a metabolomics risk score (MRS) that predicts MCI, potentially identifying a different set of metabolites than those discovered in individual-metabolite analysis. Results: We identified 20 metabolites predicting prevalent MCI and/or global cognitive change. Six of them were novel and 14 were previously reported as associated with neurocognitive aging outcomes. The MCI MRS comprised 61 metabolites and improved prediction accuracy from 84% (minimally adjusted model) to 89% in the entire dataset and from 75% to 87% among apolipoprotein E ε4 carriers. Discussion: Blood metabolites may serve as biomarkers identifying individuals at risk for MCI among US Hispanics/Latinos.

Original language	English (US)
Article number	e12259
Journal	Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume	14
Issue number	1
DOIs	https://doi.org/10.1002/dad2.12259
State	Published - 2022

Keywords

Hispanics/Latinos
global cognitive change
metabolite biomarkers
metabolomic risk score
mild cognitive impairment
risk prediction

ASJC Scopus subject areas

Clinical Neurology
Psychiatry and Mental health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/dad2.12259

Cite this

He, S., Granot-Hershkovitz, E., Zhang, Y., Bressler, J., Tarraf, W., Yu, B., Huang, T., Zeng, D., Wassertheil-Smoller, S., Lamar, M., Daviglus, M., Marquine, M. J., Cai, J., Mosley, T., Kaplan, R., Boerwinkle, E., Fornage, M., DeCarli, C., Kristal, B., ... Sofer, T. (2022). Blood metabolites predicting mild cognitive impairment in the study of Latinos-investigation of neurocognitive aging (HCHS/SOL). Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 14(1), Article e12259. https://doi.org/10.1002/dad2.12259

He, S, Granot-Hershkovitz, E, Zhang, Y, Bressler, J, Tarraf, W, Yu, B, Huang, T, Zeng, D, Wassertheil-Smoller, S, Lamar, M, Daviglus, M, Marquine, MJ, Cai, J, Mosley, T, Kaplan, R, Boerwinkle, E, Fornage, M, DeCarli, C, Kristal, B, Gonzalez, HM & Sofer, T 2022, 'Blood metabolites predicting mild cognitive impairment in the study of Latinos-investigation of neurocognitive aging (HCHS/SOL)', Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, vol. 14, no. 1, e12259. https://doi.org/10.1002/dad2.12259

@article{79cfe4fe1b374957aa5060592916643c,

title = "Blood metabolites predicting mild cognitive impairment in the study of Latinos-investigation of neurocognitive aging (HCHS/SOL)",

abstract = "Introduction: Blood metabolomics-based biomarkers may be useful to predict measures of neurocognitive aging. Methods: We tested the association between 707 blood metabolites measured in 1451 participants from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL), with mild cognitive impairment (MCI) and global cognitive change assessed 7 years later. We further used Lasso penalized regression to construct a metabolomics risk score (MRS) that predicts MCI, potentially identifying a different set of metabolites than those discovered in individual-metabolite analysis. Results: We identified 20 metabolites predicting prevalent MCI and/or global cognitive change. Six of them were novel and 14 were previously reported as associated with neurocognitive aging outcomes. The MCI MRS comprised 61 metabolites and improved prediction accuracy from 84% (minimally adjusted model) to 89% in the entire dataset and from 75% to 87% among apolipoprotein E ε4 carriers. Discussion: Blood metabolites may serve as biomarkers identifying individuals at risk for MCI among US Hispanics/Latinos.",

keywords = "Hispanics/Latinos, global cognitive change, metabolite biomarkers, metabolomic risk score, mild cognitive impairment, risk prediction",

author = "Shan He and Einat Granot-Hershkovitz and Ying Zhang and Jan Bressler and Wassim Tarraf and Bing Yu and Tianyi Huang and Donglin Zeng and Sylvia Wassertheil-Smoller and Melissa Lamar and Martha Daviglus and Marquine, {Maria J.} and Jianwen Cai and Thomas Mosley and Robert Kaplan and Eric Boerwinkle and Myriam Fornage and Charles DeCarli and Bruce Kristal and Gonzalez, {Hector M.} and Tamar Sofer",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.",

year = "2022",

doi = "10.1002/dad2.12259",

language = "English (US)",

volume = "14",

journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",

issn = "2352-8729",

publisher = "Elsevier BV",

number = "1",

}

TY - JOUR

T1 - Blood metabolites predicting mild cognitive impairment in the study of Latinos-investigation of neurocognitive aging (HCHS/SOL)

AU - He, Shan

AU - Granot-Hershkovitz, Einat

AU - Zhang, Ying

AU - Bressler, Jan

AU - Tarraf, Wassim

AU - Yu, Bing

AU - Huang, Tianyi

AU - Zeng, Donglin

AU - Wassertheil-Smoller, Sylvia

AU - Lamar, Melissa

AU - Daviglus, Martha

AU - Marquine, Maria J.

AU - Cai, Jianwen

AU - Mosley, Thomas

AU - Kaplan, Robert

AU - Boerwinkle, Eric

AU - Fornage, Myriam

AU - DeCarli, Charles

AU - Kristal, Bruce

AU - Gonzalez, Hector M.

AU - Sofer, Tamar

PY - 2022

Y1 - 2022

N2 - Introduction: Blood metabolomics-based biomarkers may be useful to predict measures of neurocognitive aging. Methods: We tested the association between 707 blood metabolites measured in 1451 participants from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL), with mild cognitive impairment (MCI) and global cognitive change assessed 7 years later. We further used Lasso penalized regression to construct a metabolomics risk score (MRS) that predicts MCI, potentially identifying a different set of metabolites than those discovered in individual-metabolite analysis. Results: We identified 20 metabolites predicting prevalent MCI and/or global cognitive change. Six of them were novel and 14 were previously reported as associated with neurocognitive aging outcomes. The MCI MRS comprised 61 metabolites and improved prediction accuracy from 84% (minimally adjusted model) to 89% in the entire dataset and from 75% to 87% among apolipoprotein E ε4 carriers. Discussion: Blood metabolites may serve as biomarkers identifying individuals at risk for MCI among US Hispanics/Latinos.

AB - Introduction: Blood metabolomics-based biomarkers may be useful to predict measures of neurocognitive aging. Methods: We tested the association between 707 blood metabolites measured in 1451 participants from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL), with mild cognitive impairment (MCI) and global cognitive change assessed 7 years later. We further used Lasso penalized regression to construct a metabolomics risk score (MRS) that predicts MCI, potentially identifying a different set of metabolites than those discovered in individual-metabolite analysis. Results: We identified 20 metabolites predicting prevalent MCI and/or global cognitive change. Six of them were novel and 14 were previously reported as associated with neurocognitive aging outcomes. The MCI MRS comprised 61 metabolites and improved prediction accuracy from 84% (minimally adjusted model) to 89% in the entire dataset and from 75% to 87% among apolipoprotein E ε4 carriers. Discussion: Blood metabolites may serve as biomarkers identifying individuals at risk for MCI among US Hispanics/Latinos.

KW - Hispanics/Latinos

KW - global cognitive change

KW - metabolite biomarkers

KW - metabolomic risk score

KW - mild cognitive impairment

KW - risk prediction

UR - http://www.scopus.com/inward/record.url?scp=85137238203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85137238203&partnerID=8YFLogxK

U2 - 10.1002/dad2.12259

DO - 10.1002/dad2.12259

M3 - Article

AN - SCOPUS:85137238203

SN - 2352-8729

VL - 14

JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

IS - 1

M1 - e12259

ER -

Blood metabolites predicting mild cognitive impairment in the study of Latinos-investigation of neurocognitive aging (HCHS/SOL)

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this